医学
乳腺癌
激素受体
肿瘤科
内科学
佐剂
癌症
激素
雌激素受体
疾病
激素疗法
雌激素
激素疗法
作者
Chiara Tommasi,Giulia Airò,Fabiana Pratticò,Irene Testi,Matilde Corianò,Benedetta Pellegrino,Nerina Denaro,Laura Demurtas,Mariele Dessì,Sara Murgia,Gianni Mura,Demi Wekking,Mario Scartozzi,Antonino Musolino,Cinzia Solinas
摘要
Hormone receptor (HR)-positive/HER2-positive breast cancer represents a distinct subtype expressing estrogen and progesterone receptors with an overexpression of HER2. Approximately 14% of female breast cancer cases are HER2-positive, with the majority being HR-positive. These tumors show a cross-talk between the hormonal and HER2 pathways; the interaction has implications for the treatment options for the disease. In this review, we analyze the biology of HR-positive/HER2-positive breast cancer and summarize the evidence concerning the standard of care options both in neoadjuvant/adjuvant settings and in advanced disease. Additionally, we focus on new trials and drugs for HR-positive/HER2-positive breast cancer and the new entity: HER2-low breast cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI